In a recent interview with PharmaShots, Kai te Kaat, the Vice President, Head of Franchise Oncology, MDx at QIAGEN shares his insights and highlights on QIAprep& Viral RNA UM Kit. Shots: QIAGEN […]readmore
Tags : Highlights
Shots: The company highlights its lead candidate, SLN360 for CV disease associated with high Lp (a) levels and has received the US FDA’s IND approval to start dose-escalation studies in […]readmore
Shots: On Mar 19, 2020, the company initiates the global P-III study in collaboration with BARDA to assess the efficacy of Actemra/RoActemra (tocilizumab, IV) + SOC vs PBO + SOC […]readmore
1. Pfizer Launched its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019 Date – Oct 01, 2019 Product – Zirabev (biosimilar, bevacizumab) The biosimilar was launched in […]readmore
Shots: Sangamo provides an update on its pre/ clinical pipeline and emphasizes on its global capabilities across clinical science, operations, product development and manufacturing at its R&D day The company […]readmore
Shots: Novartis reports that it has 60 projects in P-II with expected 10+ products to enter in P-III study in 2020 & 2021 while 90% of them are first-in-class or […]readmore
The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer’s […]readmore
The second quarter of 2019 has ended with major acquisitions in pharma and biotech industry. Moving with the latest acquisition of Allergan for $63B by AbbVie focusing on to generate […]readmore